Rescriptor

Active Ingredient(s): Delavirdine
FDA Approved: * April 4, 1997
Pharm Company: * AGOURON
Category: HIV / AIDS

Delavirdine (DLV) (brand name Rescriptor) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by ViiV Healthcare. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. It is presented as the mesylate. The recommended dosage is 400mg, three times a day. Although delavirdine was approved by the U.S. Food and Drug Administration in 1997, its efficacy is lower than other NNRTIs, especially efavirenz, and... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Rescriptor U;3761
Rescriptor 100 mg Oral Tablet
NDC: 49702-209
Labeler:
Viiv Healthcare Company
Rescriptor RESCRIPTOR;200;mg
Rescriptor 200 mg Oral Tablet
NDC: 49702-210
Labeler:
Viiv Healthcare Company
Rescriptor RESCRIPTOR;200;mg
Rescriptor 200 mg Oral Tablet
NDC: 63010-021
Labeler:
Pharmacia and Upjohn Company
Rescriptor RESCRIPTOR;200;mg
Rescriptor 200 mg Oral Tablet
NDC: 0179-0096
Labeler:
Kaiser Foundation Hospitals
Rescriptor U;3761
Rescriptor 100 mg Oral Tablet
NDC: 63010-020
Labeler:
Pharmacia and Upjohn Company
Rescriptor 200 mg Oral Tablet
NDC: 49702-225
Labeler:
Viiv Healthcare Company